InnovaRx Innova Health Strategies

B02.29

Other postherpetic nervous system involvement

Billable FY2026 2025-10-01 → 2026-09-30
Exclusions 5 never code together
A00-B99chapter
Excludes1
  • certain localized infections - see body system-related chapters
Excludes2
  • carrier or suspected carrier of infectious disease (Z22.-)Z22.-
  • infectious and parasitic diseases complicating pregnancy, childbirth and the puerperium (O98.-)O98.-
  • infectious and parasitic diseases specific to the perinatal period (P35-P39)P35-P39
  • influenza and other acute respiratory infections (J00-J22)J00-J22

Excludes1 — never code together. The excluded condition and this one are mutually exclusive.

Excludes2 — not included here, but the patient may have both. Code both when documented.

Instructional notes 5
B02.29code
Inclusion terms
  • Postherpetic radiculopathy
B02code
Includes
  • shingles
  • zona
A00-B99chapter
Includes
  • diseases generally recognized as communicable or transmissible
Use additional code
  • code to identify resistance to antimicrobial drugs (Z16.-)Z16.-
Index entries leading here 5
  • Neuralgia, neuralgic (acute) M79.2
    • cranial
      • postherpetic, postzoster B02.29
    • postherpetic NEC B02.29
  • Herpes, herpesvirus, herpetic B00.9
  • Neuritis (rheumatoid) M79.2
    • postherpetic, postzoster B02.29
  • Radiculopathy M54.10
  • Postherpetic neuralgia (zoster) B02.29
Alongside this code 4 same parent — B02.2
Medications 5

MED-RT files conditions by MeSH, which carves the world differently from ICD-10. These are name matches on this code's description, offered as candidates — not as an assertion that they are this code.

Additional references
AHA Coding Clinic® Licence required

Official coding advice for this code. Published by the American Hospital Association. Not included in this installation.

Risk adjustment

RX08HCC168

Presence is a property of the code. Untick a model to hide it everywhere.

This code

Billable
yes
Code set
FY2026
Parent
B02.2
Block
B00-B09
Siblings
4

Present FY2024–FY2027.